Integrated Quantitative Investments LLC Makes New $305,000 Investment in MiMedx Group, Inc $MDXG

Integrated Quantitative Investments LLC bought a new stake in MiMedx Group, Inc (NASDAQ:MDXG) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 49,858 shares of the company’s stock, valued at approximately $305,000.

Other hedge funds have also recently modified their holdings of the company. New York State Common Retirement Fund grew its position in MiMedx Group by 51.8% in the 1st quarter. New York State Common Retirement Fund now owns 87,781 shares of the company’s stock valued at $667,000 after buying an additional 29,941 shares during the last quarter. Allianz Asset Management GmbH purchased a new stake in shares of MiMedx Group in the first quarter valued at about $128,000. Legato Capital Management LLC acquired a new position in shares of MiMedx Group during the first quarter worth about $101,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in MiMedx Group by 18.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,713 shares of the company’s stock worth $302,000 after purchasing an additional 6,090 shares in the last quarter. Finally, Phocas Financial Corp. lifted its position in MiMedx Group by 96.5% in the first quarter. Phocas Financial Corp. now owns 411,847 shares of the company’s stock valued at $3,130,000 after purchasing an additional 202,265 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Trading Down 1.2%

Shares of MDXG stock opened at $7.38 on Monday. MiMedx Group, Inc has a twelve month low of $5.79 and a twelve month high of $10.14. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of 27.33 and a beta of 1.70. The firm has a 50-day moving average price of $7.07 and a 200 day moving average price of $6.84. The company has a current ratio of 4.39, a quick ratio of 3.90 and a debt-to-equity ratio of 0.08.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.03) EPS for the quarter. The firm had revenue of $67.69 million for the quarter. MiMedx Group had a return on equity of 28.35% and a net margin of 10.38%. Research analysts forecast that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.

Insider Buying and Selling at MiMedx Group

In other news, insider Kimberly Maersk-Moller sold 58,300 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $7.42, for a total transaction of $432,586.00. Following the sale, the insider owned 236,982 shares in the company, valued at $1,758,406.44. This trade represents a 19.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Cantor Fitzgerald raised their price objective on shares of MiMedx Group from $11.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Weiss Ratings reiterated a “hold (c+)” rating on shares of MiMedx Group in a research report on Thursday. Finally, Wall Street Zen raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 2nd. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, MiMedx Group has a consensus rating of “Moderate Buy” and an average price target of $12.00.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.